Clinical Study on Degu Insulin Combined with Sitagliptin Phosphate/Metformin Hydrochloride in the Treatment of Refrac-tory Type 2 Diabetes Mellitus
Objective To explore the clinical effect of Degu insulin combined with sitagliptin phosphate/metformin hydrochloride in the treatment of patients with refractory type 2 diabetes mellitus.Methods 84 patients with refractory type 2 diabetes mellitus admitted to our hospital from May 2021 to March 2023 were selected and randomly divided into experimental group(42 cases)and reference group(42 cases).The reference group was treated with sitagliptin phosphate/metformin hydrochloride,and the experimental group was treated with Degu insulin combined with sitagliptin phosphate/metformin hydrochloride.The blood glucose levels and hypoglycemia were compared between the two groups.Results After 12 weeks of treatment,the fasting blood glucose(FPG),2-hour postprandial blood glucose(2hPBG),and hemoglobin(HbA1c)levels of the two groups decreased,and the FPG,2hPBG,and HbA1c levels of the experimental group were lower than those of the reference group(P<0.05).During the treatment,no statistical difference was found in the incidence of hypoglycemia(11.90%vs.9.52%)between the two groups(P>0.05).Conclusions Degu insulin combined with sitagliptin phosphate/metformin hydrochloride has better glycemic control effect in the treatment of patients with refractory type 2 diabetes mellitus,and does not significantly increase the risk of hypoglycemia in patients with higher safety,which is worthy of clinical promotion.
Refractory type 2 diabetes mellitusSitagliptin phosphate/metformin hydrochlorideDegu insulinTreatment effect
国家科技期刊平台
NSTL
万方数据
